Chase Pharmaceuticals Corporation

Chase Pharmaceuticals Corporation is a biopharmaceutical company focused on developing innovative therapies to treat neurological disorders, leveraging scientific research to enhance patient care. Founded in 2007 in Washington, US, Chase Pharmaceuticals Corporation specializes in creating treatments for neurological conditions. The company has undergone significant growth and was involved in a notable Trade Sale in November 2016, where Allergan Inc acquired a stake from Cipla Ventures for USD 125 mn. Chase has completed a total of 4 deals since its inception.

The company is independent and does not have any known subsidiaries or parent companies. Chase Pharmaceuticals Corporation is dedicated to the research and development of advanced therapies targeting neurological disorders. Their product focus is on creating innovative solutions that address complex health challenges faced by patients with such conditions. The company aims to provide effective treatment options through its scientific advancements and clinical trials.

Chase Pharmaceuticals generates revenue through the strategic partnerships and collaborations established for the distribution of its therapies. By focusing on innovative treatments for neurological disorders, the company aims to enhance its market presence and revenue streams in the biopharmaceutical landscape. Revenue is primarily driven by the demand for its specialized therapies and successful partnerships with key industry players. Chase Pharmaceuticals Corporation intends to leverage its recent funding from Allergan Inc to further its R&D initiatives, focusing on developing new therapies for neurological disorders.

The company plans to explore expansion into additional markets, aiming for growth in North America and Europe by 2025. The recent Trade Sale of USD 125 mn will be utilized to support the launch of upcoming products, enhancing their portfolio and meeting patient needs.